Leuprorelin depot - Foresee/ScinoPharma

Drug Profile

Leuprorelin depot - Foresee/ScinoPharma

Alternative Names: FP-001; FP-001 LMIS; leuprolide controlled-release - Foresee/ScinoPharma; Leuprolide Mesylate - Foresee/ScinoPharma

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Foresee Pharmaceuticals - ScinoPharm (JV)
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 27 Sep 2017 Leuprorelin depot market-licensed to TRPharm in Turkey and some countries in the Middle East
  • 08 Sep 2017 Foresee Pharmaceuticals initiates a phase III trial for Prostate cancer (Late-stage disease) in USA (NCT03261999)
  • 19 Aug 2017 Foresee Pharmaceuticals plans a phase III trial for Prostate cancer (Late-stage disease) in USA, Czech Republic, Lithuania, Slovakia (SC) (NCT03261999)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top